CAS: 916975-92-3; 4-Methyl-1-(3-Nitro-5-(Trifluoromethyl)Phenyl)-1H-Imidazole

该化合物是一种化学化合物,其特点是有5个成分的单体环环,含有两个氮原子;该化合物的特征是:一个四分位的甲基组,一个以硝基组替代的苯基组,另一个一位的三氟甲基组;该硝基化合物的存在带来了巨大的极化和氢联结潜力,而三氟硫基组则增强了脂性,能够影响化合物的回动和生物活动;该二分体以其在各种生物系统中的作用而著称,包括作为制药的建筑块,该化合物可能具有有趣的药理特性,使其成为医学化学的一个对象;其独特的结构特征表明,在药物开发方面,特别是在针对特定生物路径或受体方面,可能具有潜在用途.

结构式图片

相似化合物

641571-11-1 917391-29-8 351324-52-2

欧盟法规

REACH注册ECHA物质ECHA物质

上下游产品

CAS号822-36-6 4-甲基咪唑 | CAS号401-99-0 3,5-二硝基三氟甲苯 | CAS号630125-49-4 3-溴-5-硝基三氟甲苯 | CAS号454-73-9 3-氟-5-硝基三氟甲苯 | CAS号641571-11-1 3-(4-甲基-1H-咪唑-1...

合成工艺路线路线简述

    📜三氟甲苯置于8-羟基异喹啉,Copper(L) Iodide,硫酸,溴,硝酸,Potassium Carbonate,三乙胺体系中,用 N,N-二甲基甲酰胺 作为反应溶剂,化学反应 27.0H,反应生成 4-甲基-1-(3-硝基-5-三氟甲基-苯基)-1H-咪唑
    参考文献:Method For Preparing Nilotinib Intermediate
    标题:Method For Preparing Nilotinib Intermediate
    摘要:本发明公开了一种制备尼洛替尼中间体3-(4-甲基-1H-咪唑-1-基)-5-三氟甲基苯胺(I)的方法.该方法包括以下步骤:以三氟甲基甲苯为原料,通过硝化,溴化,缩合和还原依次制备尼洛替尼中间体(I).与现有技术相比,该制备方法具有以下优点:产率相对较高,原材料易获得,工艺简洁,副反应少,适合工业生产,促进了大宗药物的经济技术发展.

    海关参考信息

    专利信息


    专利号:US-7709657-B2
    优先权日:2005-06-09
    标 题:Process for the synthesis of organic compounds
    发明人:ACEMOGLU MURAT; SCHENKEL BERTHOLD; SHIEH WEN-CHUNG; XUE SONG; WIDMER ERICH; GARCIA FUENTES PEDRO; MARTIN MEDINA JOSE; VICENTE BANOS FRANCISCO
    权利人:NOVARTIS AG
    摘要:The present invention provides an efficient, safe and cost effective way to prepare 5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine which is an intermediate for the preparation of substituted pyrimidinylaminobenzamides of formula (II):

    专利号:US-11414388-B2
    优先权日:2018-04-10
    标 题:Crystal form of 3-(4-methyl-1h-imidazol-1-yl)-5-trifluoromethylaniline monohydrochloride and use thereof
    发明人:NIU DELIANG; MA BOJUN; ZHU ZHANQUN; WAN QIANG
    权利人:ARIZEST SHANGHAI PHARMATECH CO LTD; JIANGSU XIDI PHARMACEUTICALS CO LTD; SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP CO LTD
    摘要:The present invention relates to a crystal form of 3-(4-methyl-1H-imidazol-1-yl)-5-trifluoromethylaniline monohydrochloride and the use thereof. Specifically, disclosed are a crystal form A of a monohydrochloride anhydrous substance of 3-(4-methyl-1H-imidazol-1-yl)-5-trifluoromethylaniline monohydrochloride, a method for preparing the crystal form A and the use of the crystal form in the synthesis of nilotinib. The crystal form A of the present invention has good stability and purity, and can be directly used in the preparation and production of nilotinib. The method for preparing nilotinib in the present invention is easy to operate and has high industrial application value.

    专利号:US-8008504-B2
    优先权日:2005-06-09
    标题 :Process for the synthesis of organic compounds
    发明人:ABEL STEPHAN; ACEMOGLU MURAT; ERB BERNHARD; KRELL CHRISTOPH; SCLAFANI JOSEPH; MEISENBACH MARK; PRASHAD MAHAVIR; SHIEH WEN-CHUNG; XUE SONG
    权利人:NOVARTIS AG
    摘要:The present invention provides an efficient, safe and cost effective way to prepare 5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine which is a key intermediate for the preparation of substituted pyrimidinylaminobenzamides of formula (II):

    专利号:US-2008200692-A1
    优先权日:2005-06-09
    标 题:Process For the Synthesis of Organic Compounds

    专利号:ES-2465522-T3
    优先权日:2005-06-09
    标 题:Process for the synthesis of organic compounds

    专利号:CA-2611280-A1
    优先权日:2005-06-09
    标题 :Processes for the synthesis of 5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine and its intermediates

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:S100 | PFASREACH | List of PFAS identified in REACH 2019 | DOI:10.5281/zenodo.7426856
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知